Foundational amino acid with interesting longevity angles that haven’t moved beyond rodents
Glycine is as basic as it gets. The simplest proteinogenic amino acid, it shows up everywhere in biology: glycinergic inhibitory neurotransmission, hepatic conjugation reactions, heme precursor synthesis, structural collagen content. Its ubiquity is also the problem. When evaluating a compound as a serious research target, “it does a lot of things reasonably well” isn’t a ringing endorsement. It’s a description of a nutrient.
The two angles that generate any real interest here are the methionine restriction mimetic story and the NMDA glycine-site co-agonism. We think the methionine restriction angle is genuinely interesting biology. Methionine restriction reliably extends lifespan in rodents, and the mechanism involves suppressed methionine flux through the transmethylation pathway. Glycine supplementation at 5-10 g/day can shift that flux by enhancing one-carbon transfer reactions, producing a metabolic phenotype that approximates dietary methionine restriction without actually restricting methionine intake. The Brind group published the core preclinical rationale around 2011, and subsequent work has continued to support the rodent model. The problem is that its been well over a decade and human longevity data is essentially nonexistent. This is a promising story in mice that hasnt moved.
The NMDA co-agonist angle is less exciting than it sounds. Glycine binds the modulatory glycine site on NMDA receptors, the same site targeted by more interesting compounds like D-cycloserine or GLYX-13. Bannai et al. (2012) showed 3 g before bed improved subjective sleep quality and reduced daytime sleepiness in a small Japanese cohort. Real effect, real mechanism, modest replication in subsequent work. But as a probe for NMDA biology, glycine is outclassed by D-serine, which carries roughly three-fold higher affinity at GluN2B-containing receptors, and by more selective pharmacological tools developed since. You’d use glycine here only if cost and sourcing are the binding constraints.
Differentiation is the core issue. Glycine is priced at pennies per gram, freely available from dozens of food-grade suppliers, and studied across hundreds of labs over decades. There’s no axis where it clearly bests alternatives. For NMDA research, D-serine and GLYX-13 are better probes. For longevity and methionine restriction work, alpha-ketoglutarate and caloric restriction mimetics are further along the clinical pipeline. For sleep, there are more studied interventions.
Even then, the frontier work is upstream of glycine, not in it. It’s a supporting player, not a lead compound.